140 related articles for article (PubMed ID: 9195565)
1. Melphalan dosing regimens for management of recurrent melanoma by isolated limb perfusion: application of a physiological pharmacokinetic model based on melphalan distribution in the isolated perfused rat hindlimb.
Wu ZY; Smithers BM; Roberts MS
Melanoma Res; 1997 Jun; 7(3):252-64. PubMed ID: 9195565
[TBL] [Abstract][Full Text] [Related]
2. Tissue and perfusate pharmacokinetics of melphalan in isolated perfused rat hindlimb.
Wu ZY; Smithers BM; Roberts MS
J Pharmacol Exp Ther; 1997 Sep; 282(3):1131-8. PubMed ID: 9316818
[TBL] [Abstract][Full Text] [Related]
3. Isolated limb perfusion with melphalan for human melanoma xenografts in the hindlimb of nude rats: a surviving animal model.
Wu Z; Roberts MS; Parsons PG; Smithers BM
Melanoma Res; 1997 Feb; 7(1):19-26. PubMed ID: 9067961
[TBL] [Abstract][Full Text] [Related]
4. The effects of perfusion conditions on melphalan distribution in the isolated perfused rat hindlimb bearing a human melanoma xenograft.
Wu ZY; Smithers BM; Parsons PG; Roberts MS
Br J Cancer; 1997; 75(8):1160-6. PubMed ID: 9099965
[TBL] [Abstract][Full Text] [Related]
5. [Melphalan pharmacokinetics during isolated limb regional perfusion in patients with skin melanoma and soft tissue sarcoma].
Gafton GI; Senchik KY; Petrov VG; V V Semiglazov ; N V Tatyanicheva ; V G Bespalov ; Semiletova YV; Gafton IG; Zinoviev GV; Kireeva GS
Vopr Onkol; 2015; 61(6):932-6. PubMed ID: 26995981
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of melphalan in isolated limb perfusion.
Norda A; Loos U; Sastry M; Goehl J; Hohenberger W
Cancer Chemother Pharmacol; 1999; 43(1):35-42. PubMed ID: 9923539
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of melphalan in isolated limb infusion for recurrent localized limb malignancy.
Roberts MS; Wu ZY; Siebert GA; Anissimov YG; Thompson JF; Smithers BM
Melanoma Res; 2001 Aug; 11(4):423-31. PubMed ID: 11479432
[TBL] [Abstract][Full Text] [Related]
8. Determinants of acute regional toxicity following isolated limb perfusion for melanoma.
Thompson JF; Eksborg S; Kam PC; Ingvar C; Yau DF; Lai DT; Ramzan I
Melanoma Res; 1996 Jun; 6(3):267-71. PubMed ID: 8819130
[TBL] [Abstract][Full Text] [Related]
9. Can tissue drug concentrations be monitored by microdialysis during or after isolated limb perfusion for melanoma treatment?
Wu ZY; Smithers BM; Anderson C; Roberts MS
Melanoma Res; 2000 Feb; 10(1):47-54. PubMed ID: 10711640
[TBL] [Abstract][Full Text] [Related]
10. Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb.
Klaase JM; Kroon BB; Beijnen JH; van Slooten GW; van Dongen JA
Br J Cancer; 1994 Jul; 70(1):151-3. PubMed ID: 8018528
[TBL] [Abstract][Full Text] [Related]
11. Relative dispersion of intravascular transit times during isolated human limb perfusions for recurrent melanoma.
Roberts MS; Wu ZY; Rivory LP; Smithers BM; Egerton WS; Weiss M
Br J Clin Pharmacol; 1997 Oct; 44(4):347-51. PubMed ID: 9354309
[TBL] [Abstract][Full Text] [Related]
12. [Isolated hyperthermic limb perfusion with melphalan and tumor necrosis factor in malignant melanoma].
Kettelhack C; Hohenberger P; Schlag PM
Dtsch Med Wochenschr; 1997 Feb; 122(7):177-81. PubMed ID: 9072487
[TBL] [Abstract][Full Text] [Related]
13. Melphalan monitoring during hyperthermic perfusion of isolated limb for melanoma: pharmacokinetic study and 99mTc-albumin microcolloid technique.
Cattel L; Buffa E; De Simone M; Cesana P; Novello S; Dosio F; Ceruti M
Anticancer Res; 2001; 21(3C):2243-8. PubMed ID: 11501854
[TBL] [Abstract][Full Text] [Related]
14. A clinical and pharmacokinetic study of isolated limb perfusion with heat and melphalan for melanoma.
Minor DR; Allen RE; Alberts D; Peng YM; Tardelli G; Hutchinson J
Cancer; 1985 Jun; 55(11):2638-44. PubMed ID: 3995475
[TBL] [Abstract][Full Text] [Related]
15. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs.
Klop WM; Vrouenraets BC; van Geel BN; Eggermont AM; Klaase JM; Nieweg OE; Kroon BB
J Am Coll Surg; 1996 Jun; 182(6):467-72. PubMed ID: 8646345
[TBL] [Abstract][Full Text] [Related]
16. Melphalan concentration and distribution in the tissues of tumour-bearing limbs treated by isolated limb perfusion.
Scott RN; Blackie R; Kerr DJ; Hughes J; Burnside G; MacKie RM; Byrne DS; McKay AJ
Eur J Cancer; 1992; 28A(11):1811-3. PubMed ID: 1389515
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of isolated lung perfusion with melphalan for resectable pulmonary metastases, a phase I and extension trial.
Grootenboers MJ; Hendriks JM; van Boven WJ; Knibbe CA; van Putte B; Stockman B; De Bruijn E; Vermorken JB; Van Schil PE; Schramel FM
J Surg Oncol; 2007 Dec; 96(7):583-9. PubMed ID: 17999399
[TBL] [Abstract][Full Text] [Related]
18. A comparison of dosimetric methods in isolated limb perfusion with melphalan for malignant melanoma of the lower extremity.
Byrne DS; McKay AJ; Blackie R; MacKie RM
Eur J Cancer; 1996 Nov; 32A(12):2082-7. PubMed ID: 9014749
[TBL] [Abstract][Full Text] [Related]
19. Saturable dose-response relationships for melphalan in melanoma treatment by isolated limb infusion in the nude rat.
Roberts MS; Wu ZY; Siebert GA; Thompson JF; Smithers BM
Melanoma Res; 2001 Dec; 11(6):611-8. PubMed ID: 11725207
[TBL] [Abstract][Full Text] [Related]
20. In-transit melanoma: the role of alkylating-agent resistance in regional therapy.
Grubbs EG; Abdel-Wahab O; Cheng TY; Abdel-Wahab Z; Peterson B; Pruitt SK; Colvin OM; Friedman HS; Tyler DS
J Am Coll Surg; 2004 Sep; 199(3):419-27. PubMed ID: 15325612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
